Back to Browse Journals » Biologics: Targets and Therapy » Volume 7

Clinical utility of asthma biomarkers: from bench to bedside

Authors Vijverberg SJH, Hilvering B, Raaijmakers JA, Lammers JW, Maitland-van der Zee AH, Koenderman L

Published Date August 2013 Volume 2013:7 Pages 199—210

DOI http://dx.doi.org/10.2147/BTT.S29976

Received 10 April 2013, Accepted 29 May 2013, Published 29 August 2013

Susanne JH Vijverberg,1,2,* Bart Hilvering,2,* Jan AM Raaijmakers,1 Jan-Willem J Lammers,2 Anke-Hilse Maitland-van der Zee,1,* Leo Koenderman2,*

1Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands; 2Department of Respiratory Medicine, University Medical Centre Utrecht, Utrecht, The Netherlands

*These authors contributed equally to this work

Abstract: Asthma is a chronic disease characterized by airway inflammation, bronchial hyperresponsiveness, and recurrent episodes of reversible airway obstruction. The disease is very heterogeneous in onset, course, and response to treatment, and seems to encompass a broad collection of heterogeneous disease subtypes with different underlying pathophysiological mechanisms. There is a strong need for easily interpreted clinical biomarkers to assess the nature and severity of the disease. Currently available biomarkers for clinical practice – for example markers in bronchial lavage, bronchial biopsies, sputum, or fraction of exhaled nitric oxide (FeNO) – are limited due to invasiveness or lack of specificity. The assessment of markers in peripheral blood might be a good alternative to study airway inflammation more specifically, compared to FeNO, and in a less invasive manner, compared to bronchoalveolar lavage, biopsies, or sputum induction. In addition, promising novel biomarkers are discovered in the field of breath metabolomics (eg, volatile organic compounds) and (pharmaco)genomics. Biomarker research in asthma is increasingly shifting from the assessment of the value of single biomarkers to multidimensional approaches in which the clinical value of a combination of various markers is studied. This could eventually lead to the development of a clinically applicable algorithm composed of various markers and clinical features to phenotype asthma and improve diagnosis and asthma management.

Keywords: asthma, airway inflammation, biological markers, pharmacogenomics, metabolomics

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Treatment and management of myelofibrosis in the era of JAK inhibitors

Keohane C, Radia DH, Harrison CN

Biologics: Targets and Therapy 2013, 7:189-198

Published Date: 20 August 2013

Cross-reactivity of human monoclonal antibodies generated with peripheral blood lymphocytes from dengue patients with Japanese encephalitis virus

Pipattanaboon C, Sasaki T, Nishimura M, Setthapramote C, Pitaksajjakul P, Leaungwutiwong P, Limkittikul K, Puiprom O, Sasayama M, Chaichana P, Okabayashi T, Kurosu T, Ono K, Ramasoota P, Ikuta K

Biologics: Targets and Therapy 2013, 7:175-187

Published Date: 15 August 2013

Tivozanib in the treatment of renal cell carcinoma

Hepgur M, Sadeghi S, Dorff TB, Quinn DI

Biologics: Targets and Therapy 2013, 7:139-148

Published Date: 11 June 2013

New and emerging treatments for ulcerative colitis: a focus on vedolizumab

Gledhill T, Bodger K

Biologics: Targets and Therapy 2013, 7:123-130

Published Date: 23 May 2013

Bosutinib in the management of chronic myelogenous leukemia

Keller-von Amsberg G, Schafhausen P

Biologics: Targets and Therapy 2013, 7:115-122

Published Date: 6 May 2013

Hereditary angioedema: epidemiology, management, and role of icatibant

Ghazi A, Grant JA

Biologics: Targets and Therapy 2013, 7:103-113

Published Date: 3 May 2013

Clinical use of crizotinib for the treatment of non-small cell lung cancer

Roberts PJ

Biologics: Targets and Therapy 2013, 7:91-101

Published Date: 26 April 2013

Cetuximab: its unique place in head and neck cancer treatment

Specenier P, Vermorken JB

Biologics: Targets and Therapy 2013, 7:77-90

Published Date: 15 April 2013

Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective, long-term, follow-up study

Cantini F, Niccoli L, Cassara E, Kaloudi O, Nannini C

Biologics: Targets and Therapy 2013, 7:1-6

Published Date: 4 January 2013